WO2011056725A1 - Dérivés de pyridine et leurs procédés d'utilisation - Google Patents

Dérivés de pyridine et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2011056725A1
WO2011056725A1 PCT/US2010/054687 US2010054687W WO2011056725A1 WO 2011056725 A1 WO2011056725 A1 WO 2011056725A1 US 2010054687 W US2010054687 W US 2010054687W WO 2011056725 A1 WO2011056725 A1 WO 2011056725A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
compound
amino
hydroxy
optionally substituted
Prior art date
Application number
PCT/US2010/054687
Other languages
English (en)
Inventor
Yong Rae Hong
Mi Jung Lee
Jeong Mi Kim
Soobong Park
Wheeseong Lee
Jong-Ryoo Choi
Seonggu Ro
Joong Myung Cho
Hiroko Masamune
Gary T. Elliott
Original Assignee
Crystalgenomics, Inc.
Palkion, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics, Inc., Palkion, Inc. filed Critical Crystalgenomics, Inc.
Publication of WO2011056725A1 publication Critical patent/WO2011056725A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the present invention is in the field of pharmaceutical chemistry, and particularly in the field of compounds that affect the stability of hypoxia inducible factor-a (HIF-a) and the expression of HIF -regulated genes, and methods of using the same for the treatment of disease.
  • HIF-a hypoxia inducible factor-a
  • hypoxia-inducible factor (HIF) family of transcription factors play a central regulatory role in the control of the intracellular response to hypoxia, throughout the body.
  • HIF itself is primarily regulated by prolyl hydroxylases (PHDs), as well as asparaginyl hydroxylases.
  • PHDs prolyl hydroxylases
  • these PHDs site specifically hydroxylate the alpha subunit of HIF, which ultimately results in its degradation.
  • the body continually expresses and degrades the HIF alpha protein.
  • Modulation of PHD via the compounds disclosed herein will alter the regulation of cellular oxygen homeostasis. This has utility in any disease state where ischemia, hypoxia, and/or anemia plays a role
  • n 0 or 1 ;
  • Ri is -ORn or halo
  • R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, halo, and cyano;
  • R 3 is hydrogen or -ORn
  • Xi is selected from the group consisting of oxygen, and sulfur;
  • X 2 X 3 , X 4 and X5 are each independently nitrogen or carbon, provided that at least one of X 2 , X 3 , X 4 and X 5 is carbon;
  • R 6 and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, halo, -ORn, and cyano; provided that 5 does not exist when X 2 is nitrogen and R 7 does not exist when X 3 is nitrogen and
  • Rn is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • R 4 and R 5 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • Rio is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • compositions comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and a physiologically acceptable carrier, diluent, or excipient.
  • a subject in addition, disclosed are methods of controlling HIF levels in a subject, inhibiting hydroxylation of HIFa in a subject, inhibiting prolyl hydroxylases in a subject, modulating expression of HIF-controlled genes in a subject, treating an HIF- related disorder in a subject, treating diseases associated with ischemia, hypoxia and/or anemia, treating conditions in a subject associated with angiogenesis and/or erythropoietin levels, or treating a disorder in a subject, the method comprising identifying a subject in need thereof and administering to the subject, or contacting the subject with, at least one compound of Formula I, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
  • pharmaceutically acceptable salt means those salts of compounds of the invention that are safe and effective for use in a subject and that possess the desired biological activity.
  • Pharmaceutically acceptable salts include salts of acidic or basic groups present in compounds of the invention.
  • Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p- toluenesulfonate and pamoate (i.e., 1,1 '
  • Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts.
  • esters refers to a chemical moiety with formula -(R) n -COOR', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1.
  • An "amide” is a chemical moiety with formula -(R) n -C(0)NHR' or -(R) n -NHC(0)R', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1.
  • An amide may be an amino acid or a peptide molecule attached to a molecule of the present invention, thereby forming a prodrug.
  • Any amine, hydroxyl, or carboxyl side chain on the compounds of the present invention can be esterified or amidified.
  • the procedures and specific groups to be used to achieve this end is known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3.sup.rd Ed., John Wiley & Sons, New York, N.Y., 1999, which is incorporated herein in its entirety.
  • a “prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • substituent is a group that may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (hetereoalicyclyl)alkyl, hydroxyl, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-s
  • C m -C n in which "m” and “n” are integers refers to the number of carbon atoms in an alkyl, alkenyl or alkynyl group or the number of carbon atoms in the ring of a cycloalkyl, cycloalkenyl, or aryl group. That is, the alkyl, alkenyl, alkynyl, ring of the cycloalkyl, ring of the cycloalkenyl, or of the aryl can contain from “m” to "n", inclusive, carbon atoms.
  • a "C 1 -C 4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 -, CH 3 CH 2 -, CH 3 CH 2 CH 2 -, CH 3 CH(CH 3 )-, CH 3 CH 2 CH 2 CH 2 -, CH 3 CH 2 CH(CH 3 )-, and (CH 3 ) 3 CH-. If no "m” and "n” are designated with regard to an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl group, the broadest range described in these definitions is to be assumed.
  • alkyl refers to a straight or branched chain fully saturated (no double or triple bonds) hydrocarbon (all carbon) group.
  • alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl.
  • an alkyl group of this invention may be substituted or unsubstituted.
  • the substituent group(s) may be one or more group(s) independently selected from cycloalkyl, aryl, heteroaryl, heteroalicyclyl, hydroxyl, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, oxo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, -NR a R b , protected hydroxyl, protected amino
  • substituted alkyl groups include, without limitation, 2-oxo- prop-l-yl, 3-oxo-but-l-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl, m-trityloxymethyl, propionyloxymethyl, aminomethyl, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylaminomethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichlorobutyl, 2- aminopropyl, 1 -chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1- fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodo
  • alkenyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds.
  • alkenyl group of this invention may be unsubstituted or substituted.
  • the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution.
  • substituted alkenyl groups include, without limitation, styrenyl, 3-chloro-propen-l-yl, 3-chloro-buten-l-yl, 3- methoxy-propen-2-yl, 3-phenyl-buten-2-yl and l-cyano-buten-3-yl.
  • alkynyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more triple bonds.
  • An alkynyl group of this invention may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution.
  • cycloalkyl refers to a completely saturated (no double bonds) hydrocarbon ring. Cycloalkyl groups of this invention may range from C 3 to Cg. A cycloalkyl group may be unsubstituted or substituted. If substituted, the substituent(s) may be selected from those indicated above with regard to substitution of an alkyl group.
  • the "cycloalkyl” group can be made up of two or more fused rings (rings that share two adjacent carbon atoms). When the cycloalkyl is a fused ring system, then the ring that is connected to the rest of the molecule is a cycloalkyl as defined above. The other ring(s) in the fused ring system may be a cycloalkyl, a cycloalkenyl, an aryl, a heteroaryl, or a heteroalicyclic.
  • cycloalkenyl refers to a cycloalkyl group that contains one or more double bonds in the ring although, if there is more than one, they cannot form a fully delocalized pi-electron system in the ring (otherwise the group would be "aryl,” as defined herein).
  • a cycloalkenyl group of this invention may unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution.
  • the "cycloalkenyl” group can be made up of two or more fused rings (rings that share two adjacent carbon atoms).
  • the ring that is connected to the rest of the molecule is a cycloalkenyl as defined above.
  • the other ring(s) in the fused ring system may be a cycloalkyl, a cycloalkenyl, an aryl, a heteroaryl, or a heteroalicyclic.
  • alkylene refers to an alkyl group, as defined here, which is a biradical and is connected to two other moieties.
  • methylene -CH 2 -
  • ethylene -CH 2 CH 2 -
  • propylene -CH 2 CH 2 CH 2 -
  • isopropylene -CH 2 -CH(CH 3 )-
  • isobutylene -CH 2 -CH(CH 3 )-CH 2 -
  • cycloalkylene refers to a cycloalkyl group, as defined here, which binds in an analogous way to two other moieties.
  • alkenylene and cycloalkenylene
  • examples of acyl groups include, without limitation, formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl and benzoyl.
  • Presently preferred acyl groups are acetyl and benzoyl.
  • An acyl group of this invention may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkyl group substitution.
  • Example of substituted acyl groups include, without limitation, 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2- cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.
  • aryl refers to a carbocyclic (all carbon) ring that has a fully delocalized pi-electron system.
  • the "aryl” group can be made up of two or more fused rings (rings that share two adjacent carbon atoms). When the aryl is a fused ring system, then the ring that is connected to the rest of the molecule has a fully delocalized pi-electron system. The other ring(s) in the fused ring system may or may not have a fully delocalized pi-electron system.
  • aryl groups include, but are not limited to, benzene, naphthalene and azulene.
  • heteroaryl refers to a ring that contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur in the ring and that has a fully delocalized pi-electron system.
  • the "heteroaryl” group can be made up of two or more fused rings (rings that share two adjacent carbon atoms). When the heteroaryl is a fused ring system, then the ring that is connected to the rest of the molecule has a fully delocalized pi-electron system. The other ring(s) in the fused ring system may or may not have a fully delocalized pi-electron system.
  • heteroaryl rings include, but are not limited to, furan, thiophene, phthalazinone, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyran, pyridine, pyridazine, pyrimidine, pyrazine and triazine.
  • heterocycloalkyl refers to a ring having in the ring system one or more heteroatoms independently selected from nitrogen, oxygen and sulfur.
  • the ring may also contain one or more double bonds provided that they do not form a fully delocalized pi-electron system in the rings.
  • Heteroalicyclyl groups of this invention may be unsubstituted or substituted.
  • the substituent(s) may be one or more groups independently selected from the group consisting of halogen, hydroxyl, protected hydroxyl, cyano, nitro, alkyl, alkoxy, acyl, acyloxy, carboxy, protected carboxy, amino, protected amino, carboxamide, protected carboxamide, alkylsulfonamido and trifluoromethanesulfonamido.
  • the "heterocycloalkyl” group can be made up of two or more fused rings (rings that share two adjacent carbon atoms). When the heterocycloalkyl is a fused ring system, then the ring that is connected to the rest of the molecule is a heterocycloalkyl as defined above.
  • the other ring(s) in the fused ring system may be a cycloalkyl, a cycloalkenyl, an aryl, a heteroaryl, or a heteroalicyclic.
  • phenylalkyl refers to a phenyl ring covalently bonded to an alkyl group as defined herein.
  • examples, without limitation, of phenylalkyl groups include, without limitation, benzyl, 2-phenylethyl, 1-phenylpropyl, 4-phenylhexyl, 3- phenylamyl and 3-phenyl-2-methylpropyl.
  • Presently preferred phenylalkyl groups are those wherein the phenyl group is covalently bonded to one of the presently preferred alkyl groups.
  • a phenyl alkyl group of this invention may be unsubstituted or substituted.
  • substituted phenylalkyl groups include, without limitation, 2-phenyl-l-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)hexyl, 2- (5-cyano-3-methoxyphenyl)pentyl, 3-(2,6-dimethylphenyl)propyl, 4-chloro-3- aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)-3- (aminomethyl)pentyl and 5-phenyl-3-oxo-pent-l-yl.
  • heteroarylalkyl and “heteroalicyclylalkyl” refer to a heteroaryl or a heteroalicyclyl group covalently bonded to an alkyl group, as defined herein.
  • examples of such groups include, without limitation, 2-pyridyl ethyl, 3- pyridylpropyl, 4-furylhexyl, 3-piperazylamyl and 3-morpholinylbutyl.
  • Presently preferred heteroarylalkyl and heteroalicyclylalkyl groups are those in which a presently preferred heteroaryl or heteroalicyclyl group is covalently bonded to a presently preferred alkyl group as disclosed herein.
  • phenyl refers to a 6-member aryl group.
  • a phenyl group may be unsubstituted or substituted.
  • the substituent(s) is/are one or more, preferably one or two, group(s) independently selected from the group consisting of halogen, hydroxyl, protected hydroxyl, cyano, nitro, alkyl, alkoxy, acyl, acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, -NR a R b wherein R a and R b are as defined above but in addition R a may be an amino protecting group as defined herein, carboxamide, protected carboxamide, N-alkylcarboxamide, protected N- alkylcarboxamide, ⁇ , ⁇ -dialkylcarboxamide, trifluoromethyl, N-alkylsulfonylamino, N-(phenylsulfonyl)amino and
  • substituted phenyl groups include, without limitation, 2, 3 or 4- chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4- bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 and 4-fluorophenyl, 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxyl derivatives thereof, 2, 3 or 4-nitrophenyl; 2, 3 or 4-cyanophenyl; 2, 3 or 4-methylphenyl, 2,4- dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n- propyl)phenyl, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4- ethoxyphenyl, 2, 3 or 4-(
  • phenylalkoxy refers to a “phenylalkyl-O-" group with “phenyl” and “alkyl” as defined herein.
  • a phenylalkoxy group of this invention may be substituted or unsubstituted on the phenyl ring, in the alkyl group or both.
  • phenylalkoxy groups include, without limitation, 2-(4- hydroxyphenyl)ethoxy, 4-(4-methoxyphenyl)butoxy, (2R)-3 -phenyl-2-amino- propoxy, (2S)-3-phenyl-2-amino-propoxy, 2-indanoxy, 6-phenyl-l-hexanoxy, cinnamyloxy, 2-phenyl-l-propoxy and 2,2-dimethyl-3-phenyl-l-propoxy.
  • halo and halogen refer to the fluoro, chloro, bromo or iodo atoms. Preferred halogens are chloro and fluoro.
  • amino protecting group refers to a group commonly employed to keep (i.e., to "block” or “protect”) an amino group from reacting with a reagent while it reacts with an intended target functional group of a molecule.
  • a "protected carboxamide” refers to a carboxamide in which the nitrogen is substituted with an amino protecting group.
  • amino protecting groups include, without limitation, formyl ("For"), trityl, phthalimido, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl groups, t-butoxycarbonyl ("Boc”), 2-(4-biphenylyl)propyl-2-oxycarbonyl ("Bpoc”), 2-phenylpropyl-2-oxycarbonyl (“Poc”), 2-(4-xenyl)isopropoxycarbonyl, 1,1- diphenylethyl- 1 -oxycarbonyl, 1 , 1 -diphenylpropyl- 1 -oxycarbonyl, 2-(3 ,5- dimethoxyphenyl)propyl-2-oxycarbonyl (“Ddz”),
  • amino-protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule.
  • amino-protecting groups are Boc, Cbz and Fmoc. Descriptions of these and other amino-protecting groups may be found in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, N.Y., 1991, Chapter 7, M.
  • carboxy protecting group refers to a labile ester commonly used to block or protect a carboxylic acid while reactions are carried out on other functional groups on the compound.
  • carboxy protecting groups include, without limitation, t-butyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4- dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6- trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'- dimethoxytrityl, 4,4',4"-trimethoxytrityl, 2-phenylpropyl, trimethylsilyl, t- butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl, -(trimethylsilyl)ethyl, -(di(n- butyl)methylsilyl)ethyl, p-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, and
  • the ester employed is not critical so long as it is stable to the conditions of subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule.
  • carboxy-protecting groups are found in E. Haslam, "Protective Groups in Organic Chemistry,” J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973, Chapter 5, and T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, N.Y., 1991, Chapter 5.
  • a "hydroxyl protecting group” refers to a readily cleavable group that replaces the hydrogen of the hydroxyl group, such as, without limitation, tetrahydropyranyl, 2-methoxypropyl, 1-ethoxyethyl, methoxymethyl, 2- methoxyethoxymethyl, methylthiomethyl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'- dimethoxytrityl, 4,4',4"-trimethoxytrityl, benzyl, allyl, trimethylsilyl, (t- butyl)dimethylsilyl, and 2,2,2-trichloroethoxycarbonyl.
  • hydroxyl protecting groups are not critical so long as the derivatized hydroxyl group is stable to the conditions of subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule.
  • Further examples of hydroxyl- protecting groups are described by C. B. Reese and E. Haslam, "Protective Groups in Organic Chemistry,” J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973, Chapters 3 and 4, respectively, and T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, N.Y., 1991, Chapters 2 and 3.
  • alkylthio refers to an "alkyl-S-" group, with alkyl as defined above.
  • alkylthio group include, without limitation, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio and t-butylthio.
  • alkylsulfinyl refers to an "alkyl-SO-" group, with alkyl as defined above.
  • alkylsulfinyl groups include, without limitation, methylsulfmyl, ethylsulfmyl, n-propylsulfmyl, isopropylsulfmyl, n-butylsulfmyl and sec-butylsulfinyl.
  • alkylsulfonyl refers to an "alkyl-SCV group.
  • alkylsulfonyl groups include, without limitation, methylsulfonyl, ethylsulfonyl, n- propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, and t-butylsulfonyl.
  • phenylthio refers to a "phenyl-S-,” “phenyl-SO-,” and “phenyl-SCV” group, with phenyl as defined herein.
  • alkylaminocarbonyl groups include, without limitation, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl and butyl aminocarbonyl.
  • substituted alkylaminocarbonyl include, without limitation, methoxymethyl- aminocarbonyl, 2-chloroethylaminocarbonyl, 2-oxopropylaminocarbonyl and 4-phenylbutylaminocarbonyl.
  • substituted phenylaminocarbonyl groups include, without limitation, 2-chlorophenyl-aminocarbonyl, 3- chlorophenylaminocarbonyl, 2-nitorphenylaminocarbonyl, 4-biphenylaminocarbonyl, and 4-methoxyphenylaminocarbonyl.
  • alkylaminothio- carbonyl groups include, without limitation, methylaminothiocarbonyl, ethylaminothiocarbonyl, propylaminothiocarbonyl and butylaminothiocarbonyl.
  • alkyl-substituted alkylaminothiocarbonyl groups include, without limitation, methoxymethylaminothiocarbonyl, 2- chloroethylaminothiocarbonyl, 2-oxopropylaminothiocarbonyl and 4- phenylbutylaminothiocarbonyl .
  • phenylammothiocarbonyl groups include, without limitation, 2-chlorophenylaminothiocarbonyl, 3-chlorophenyl- aminothiocarbonyl, 2-nitrophenylaminothiocarbonyl, 4-biphenylaminothiocarbonyl and 4-methoxyphenylaminothiocarbonyl.
  • hydroxyl refers to an “-OH” group.
  • cyano refers to a "-C ⁇ N” group.
  • nitro refers to an "-N0 2 " group.
  • a "trihalomethanesulfonyl” group refers to an "X 3 CS0 2 -" group wherein X is a halogen.
  • a "thiocyanato" group refers to a "-CNS” group.
  • An "isothiocyanato" group refers to an " -NCS” group.
  • S-sulfonamido refers to a "-S0 2 NR" group with R as defined above.
  • N-sulfonamido refers to a "RS0 2 NH-" group with R as defined above.
  • a "trihalomethanesulfonamido" group refers to an "X 3 CS0 2 NR-" group with X as halogen and R as defined above.
  • perhaloalkyl refers to an alkyl group in which all the hydrogen atoms are replaced by halogen atoms.
  • an “ester” refers to a “-C(0)OR a " group with R a as defined herein.
  • an “amide” refers to a "-C(0)NR a R b " group with R a and R b as defined herein.
  • Any unsubstituted or monosubstituted amine group on a compound herein can be converted to an amide, any hydroxyl group can be converted to an ester and any carboxyl group can be converted to either an amide or ester using techniques well-known to those skilled in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, NY, 1999). Compounds containing any such converted hydroxyl, amino and/or carboxylic acid groups are within the scope of this invention.
  • an “ether” refers to an "-C-0-C-" group wherein either or both carbons may independently be part of an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heteroalicyclyl group.
  • halogenated ether refers to an ether in which the groups to either side of the oxygen are both alkyl substituted with halogen.
  • amino acid refers to any one of the twenty naturally- occurring L-amino acids, to their non-natural D-enantiomers, to non-naturally occurring amino acids such as, without limitation, norleucine ("Nle”), norvaline (“Nva”), L- or D-naphthalanine, ornithine (“Orn”), homoarginine (homoArg) and to other amino acids well-known in the peptide art such as those described in M.
  • Amino acids are referred to herein by their full chemical names, by their three letter codes, or by their one letter code, which are well-known to those skilled in the art. Unless the chirality of an amino acid is specifically designated or the amino acid is expressly stated to be a naturally occurring (i.e., L-) amino acid, the amino acid may be D or L or a racemic mixture of the two.
  • a “functionalized resin” refers to any resin to which functional groups have been appended. Such functionalized resins are well-known to those skilled in the art and include, without limitation, resins functionalized with amino, alkylhalo, formyl or hydroxyl groups.
  • Examples of functionalized resins which can serve as solid supports for immobilized solid phase synthesis are well- known in the art and include, without limitation, 4-methylbenzhydrylamine- copoly(styrene-l% divinylbenzene) (MBHA), 4-hydroxymethylphenoxymethyl- copoly(styrene- 1 % divinylbenzene), 4-oxymethyl-phenyl-acetamido-copoly(stryene- 1% divinylbenzene) (Wang), 4-(oxymethyl)-phenylacetamido methyl (Pam), and TentagelTM, from Rapp Polymere Gmbh, trialkoxy-diphenyl-methyl ester- copoly(styrene-l% divinylbenzene)(RINK) all of which are commercially available.
  • Other functionalized resins useful in the synthesis of the compounds of this invention will become apparent to those skilled in the art based on the disclosures herein. All such resins are within the scope of this invention
  • compositions comprising the racemic mixture of the two enantiomers, as well as compositions comprising each enantiomer individually substantially free of the other enantiomer.
  • contemplated herein is a composition comprising the S enantiomer substantially free of the R enantiomer, or a composition comprising the R enantiomer substantially free of the S enantiomer.
  • substantially free it is meant that the composition comprises less than 10%, or less than 8%, or less than 5%, or less than 3%, or less than 1% of the minor enantiomer.
  • compositions comprising a mixture of the various diastereomers as well as compositions comprising each diastereomer substantially free of the other diastereomers.
  • the recitation of a compound, without reference to any of its particular diastereomers includes compositions comprising all four diastereomers, compositions comprising the racemic mixture of R,R and S,S isomers, compositions comprising the racemic mixture of R,S and S,R isomers, compositions comprising the R,R enantiomer substantially free of the other diastereomers, compositions comprising the S,S enantiomer substantially free of the other diastereomers, compositions comprising the R,S enantiomer substantially free of the other diastereomers, and compositions comprising the S,R enantiomer substantially free of the other diastereomers.
  • the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically drawn or stated otherwise
  • the disclosure and claims of the present invention are based on the known general principles of chemical bonding. It is understood that the claims do not encompass structures known to be unstable or not able to exist based on the literature.
  • R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, halo, and cyano;
  • R 3 is hydrogen or -ORn
  • Xi is selected from the group consisting of oxygen, and sulfur.
  • X 2 X3, X 4 and X 5 are each independently nitrogen or carbon
  • R 6 and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, halo, -ORn, and cyano; provided that R ⁇ 5 does not exist when X 2 is nitrogen and R 7 does not exist when X3 is nitrogen and
  • R 8 does not exist when X 4 is nitrogen and R9 does not exist when X 5 is nitrogen;
  • Rn is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • R 4 and R 5 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • Rio is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • Ri is selected from the group consisting of fluoro, chloro, bromo, and iodo. In some of these embodiments, Ri is chloro.
  • Ri is-ORn and Rn is selected from the group consisting of hydrogen, and optionally substituted alkyl.
  • Rn is selected from the group consisting of hydrogen, methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
  • R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, fluoro, chloro, bromo, iodo, and cyano.
  • the alkyl group in some of these embodiments is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
  • R 2 is selected from the group consisting of hydrogen, methyl, chloro, bromo, and cyano.
  • R 3 is -ORn and Rn can be selected from the group consisting of hydrogen, and optionally substituted alkyl.
  • Rn is selected from the group consisting of hydrogen, methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
  • R 3 is hydrogen or hydroxyl.
  • R 3 is hydrogen
  • R 4 and R5 are independently hydrogen or alkyl.
  • R 4 is methyl and R 5 is hydrogen.
  • R 5 is methyl and R 4 is hydrogen.
  • both R 4 and R5 are hydrogen.
  • Xi is oxygen
  • Xi is sulfur
  • X 2 is nitrogen and R 6 does not exist.
  • X 2 is carbon and R 6 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, and optionally substituted aryl. In some of these embodiments, R 6 is hydrogen or methyl. In other embodiments, R 6 is selected from the group consisting of fluoro, chloro, bromo, and iodo.
  • X 3 is nitrogen and R 7 does not exist.
  • X 3 is carbon and R 7 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, and optionally substituted aryl. In some of these embodiments, R 7 is hydrogen. In other embodiments, R 7 is selected from the group consisting of methyl, fluoro, chloro, bromo, and iodo.
  • X 4 is nitrogen and R 8 does not exist.
  • the halo is selected from the group consisting of fluoro, chloro, bromo, and iodo.
  • R 8 is chloro.
  • the perhalohalkyl is selected from the group consisting of perfluoroalkyl, perchloroalkyl, perbromoalkyl, and periodoalkyl.
  • perhaloalkyl it is meant an alkyl moiety where all of the hydrogen atoms normally present on the alkyl are replaced by a halogen.
  • a perchloroalkyl is an alkyl moiety where all of the carbon atoms not connected to the rest of the molecule are connected to chorine atoms.
  • the alkyl moiety of the perhaloalkyl substituent is selected from the group consisting of methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
  • R 8 is trifluoromethyl .
  • X 4 is carbon and R 8 is hydrogen, chloro, methyl, trifluoromethyl.
  • R 8 is -ORn.
  • Rn is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, and tert-butyl.
  • R 8 is -OH.
  • R 8 is -N(Rn) 2 , where each Rn is independently selected from the group consisting of hydrogen, optionally substituted methyl, optionally substituted ethyl, optionally substituted n-propyl, optionally substituted isopropyl, optionally substituted n-butyl, optionally substituted sec-butyl, and optionally substituted tert-butyl.
  • R 8 is selected from the group consisting of -NH 2 , -NH(CH 3 ), -NH(CH 2 CH 3 ), -NH(CH 2 -C 6 H 5 ), -N(CH 3 ) 2 , and -N(CH 2 CH 3 ) 2 , and - ⁇ 3 ⁇ 4 2 (-N(CH(CH 3 ) 2 ) 2 ).
  • Rii is an optionally substituted alkyl, where the alkyl can be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
  • R 8 is selected from the group consisting of hydrogen, fluoro, trifluoromethyl, -OH, -NH 2 , -NH(CH 2 CH 3 ),
  • X 5 is nitrogen and R does not exist.
  • X5 is carbon and R is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, and halo.
  • the compounds disclosed herein have increased or decreased potency at HIF prolyl hydroxylases, bind the open or closed conformations of HIF pyrolyl hydroxylases, have more optimal pharmacokinetics, improved dosing schedules, less toxicity, have higher selectivity for HIF PH2 (less off-target activity), increase or decrease expression of HIF -regulated genes to a greater or lesser extent, or combinations of the preceding as compared to other HIF prolyl hydroxylase modulators.
  • SYNTHESIS [0111] in another aspect, disclosed herein is a method of synthesizing the compounds of Formula I.
  • Some of the compounds disclosed herein can be synthesized using generally accepted organic synthetic methods, including the methodology shown in Schemes 1-3, below.
  • Those of ordinary skill in the art recognize that some functional groups can be protected/deprotected using various protecting groups before a certain reaction takes place.
  • the use of these protecting groups is well-known in the art, as for example set forth in Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, N.Y., 1999, which is incorporated herein in its entirety.
  • aryl carboxylic acid derivatives may be prepared according to a variety of known synthetic methods. Some of these compounds are also commercially available from manufacturers and suppliers of reagents, such as Aldrich, Sigma, TCI, Wako, Kanto, Fluorchem, Acros, Abocado, Alfa, Fluka, etc.
  • compositions comprising a therapeutically effective amount of at least one compound of Formula I and a physiologically acceptable carrier, diluent, or excipient.
  • composition refers to a mixture of a compound disclosed herein with other chemical components, such as diluents or carriers.
  • the pharmaceutical composition facilitates administration of the compound to a subject. Multiple techniques of administering a compound exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
  • Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid and the like.
  • carrier defines a chemical compound that facilitates the incorporation of a compound into cells or tissues.
  • DMSO dimethyl sulfoxide
  • carrier facilitates the uptake of many organic compounds into the cells or tissues of a subject.
  • diot defines chemical compounds diluted in water that will dissolve the compound of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art.
  • One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.
  • physiologically acceptable defines a carrier or diluent that does not abrogate the biological activity and properties of the compound and/or is not harmful to the subject to which it is administered.
  • Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
  • compositions disclosed herein may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.
  • compositions for use in accordance with the present disclosure thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences, above.
  • the agents disclosed herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the compounds disclosed herein to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipient with pharmaceutical combination disclosed herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be used orally, include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds for use according to the present disclosure are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds to allow for the preparation of highly, concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • a pharmaceutical carrier for the hydrophobic compounds disclosed herein is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
  • a common cosolvent system used is the VPD co-solvent system, which is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • VPD co-solvent system which is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
  • co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of POLYSORBATE 80TM; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may be used.
  • hydrophobic pharmaceutical compounds may be employed.
  • Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethyl sulfoxide also may be employed, although usually at the cost of greater toxicity.
  • the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for stabilization may be employed.
  • compositions suitable for use in the methods disclosed herein include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • the exact formulation, route of administration and dosage for the pharmaceutical compositions disclosed herein can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p. 1).
  • the dose about the composition administered to the patient can be from about 0.5 to 1000 mg/kg of the patient's body weight, or 1 to 500 mg/kg, or 10 to 500 mg/kg, or 50 to 100 mg/kg of the patient's body weight.
  • the dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient.
  • human dosages for treatment of at least some condition have been established.
  • the methods disclosed herein will use those same dosages, or dosages that are between about 0.1% and 500%, or between about 25% and 250%, or between 50%) and 100% of the established human dosage.
  • a suitable human dosage can be inferred from ED 5 o or ID 5 o values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
  • the daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.1 mg and 500 mg of each ingredient, preferably between 1 mg and 250 mg, e.g. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of each ingredient between 0.01 mg and 100 mg, preferably between 0.1 mg and 60 mg, e.g. 1 to 40 mg of each ingredient of the pharmaceutical compositions disclosed herein or a pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1 to 4 times per day.
  • compositions disclosed herein may be administered by continuous intravenous infusion, preferably at a dose of each ingredient up to 400 mg per day.
  • the total daily dosage by oral administration of each ingredient will typically be in the range 1 to 2000 mg and the total daily dosage by parenteral administration will typically be in the range 0.1 to 400 mg.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety, which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC).
  • MEC minimal effective concentration
  • the MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
  • Dosage intervals can also be determined using MEC value.
  • Compositions should be administered using a regimen, which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
  • the effective local concentration of the drug may not be related to plasma concentration.
  • composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
  • compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
  • Compositions comprising a compound disclosed herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
  • methods of controlling the expression level of HIF in a cell comprising administering to the cell an amount of at least one compound of Formula I sufficient to modulate the expression level of HIF in the cell.
  • methods of controlling the expression level of HIF in a cell comprising contacting the cell with an amount of at least one compound of Formula I sufficient to modulate the expression level of HIF in the cell.
  • administering in the context of administering a compound refers to preparing a formulation, as discussed herein, containing the compound being administered, and administering the formulation by any known method to the subject or to the cell.
  • a solution containing the compound can be injected to the subject or be added to the medium containing the cells, or the subject can orally ingest a formulation containing the compound.
  • the term “contacting” refers to bringing the subject or the cell into contact with the compound.
  • a formulation of a prodrug can be administered to a subject, whereupon the prodrug undergoes metabolism. The metabolite is then either in the systemic circulation or within the cytoplasm. In this situation, the prodrug is "administered" to the subject, but both the subject and the cells are “contacted” with the metabolite.
  • a subject in another aspect, disclosed herein are methods of controlling the expression level of HIF in a subject comprising identifying a subject in need thereof and administering to the subject an amount of at least one compound of Formula I- sufficient to modulate the expression level of HIF in the subject.
  • methods of controlling the expression level of HIF in a subject comprising identifying a subject in need thereof and contacting the subject with an amount of at least one compound of Formula I- sufficient to modulate the expression level of HIF in the subject.
  • a cell comprising administering to the cell, or contacting the cell with, an amount of at least one compound of Formula I sufficient to modulate the amount of HIF in the cell.
  • methods for modulating the amount of HIF in a cell comprising administering to the cell, or contacting the cell with, an amount of at least one compound of Formula I sufficient to modulate the amount of HIF in the cell.
  • modulates refers to the ability of a compound to alter the level or concentration of HIF.
  • the modulator increases the levels, or increases the concentration of HIF in the cell.
  • the modulator lowers the levels or concentration of HIF in the cell.
  • the modulator increases the levels or concentration of HIF in the cell.
  • hydroxylation of HIFa in a cell comprising administering to the cell an amount of at least one compound of Formula I sufficient to inhibit the hydroxylation of HIFa in the cell.
  • methods of inhibiting hydroxylation of HIFa in a cell comprising contacting the cell with an amount of at least one compound of Formula I sufficient to inhibit the hydroxylation of HIFa in the cell.
  • hydroxylation of HIFa in a subject comprising identifying a subject in need thereof and administering to the subject an amount of at least one compound of Formula I sufficient to inhibit the hydroxylation of HIFa in the subject.
  • methods of inhibiting hydroxylation of HIFa in a cell comprising identifying a subject in need thereof and contacting the subject with an amount of at least one compound of Formula I sufficient to inhibit the hydroxylation of HIFa in the subject.
  • a cell comprising administering to the cell an amount of at least one compound of Formula I sufficient to modulate expression of HIF-regulated genes in the cell.
  • methods of modulate expression of HIF-regulated genes in a cell comprising contacting the cell with an amount of at least one compound of Formula I sufficient to modulate expression of HIF-regulated genes in the cell.
  • a subject in another aspect, disclosed herein are methods of modulating expression of HIF-regulated genes in a subject comprising identifying a subject in need thereof and administering to the subject an amount of at least one compound of Formula I sufficient to modulate expression of HIF-regulated genes in the subject.
  • methods of modulating expression of HIF-regulated genes in a subject comprising identifying a subject in need thereof and contacting the subject with an amount of at least one compound of Formula I sufficient to modulate expression of HIF-regulated genes in the subject.
  • disclosed herein are methods for increasing HIF levels or HIF activity in a cell comprising administering to the cell an amount of at least one compound of Formula I sufficient to increase HIF levels or HIF activity in the cell.
  • methods for increasing HIF levels or HIF activity in a cell comprising contacting the cell with an amount of at least one compound of Formula I sufficient to increase HIF levels or HIF activity in the cell.
  • disclosed herein are methods for increasing HIF levels or HIF activity in a subject comprising identifying a subject in need thereof and administering to the subject an amount of at least one compound of Formula I sufficient to increase HIF levels or HIF activity in the subject.
  • methods for increasing HIF levels or HIF activity in a subject comprising identifying a subject in need thereof and contacting the subject with an amount of at least one compound of Formula I sufficient to increase HIF levels or HIF activity in the subject.
  • HIF-related disorder in another aspect, disclosed herein are methods of treating a disorder in a subject where it is desired to modulate HIF levels or activity, the method comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods of treating an HIF -related disorder in a subject comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • HIF-related disorder is meant a disorder in which the modulation of HIF levels or activity provides a therapeutic effect.
  • the HIF-related disorder is selected from the group consisting of ischemic disorders, hypoxic disorders, anemic disorders (including, but not limited to, anemia associated with autoimmune diseases, rheumatoid arthritis, systemic lupus, chronic infections such as, without limitation, HCV, and HIV, inflammatory bowel disease, chemotherapy-induced, chronic heart disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), end stage renal disease, prematurity, hypothyroidism, malnutrition, blood disorders, including but not limited to, sickle cell anemia, and ⁇ -thalassemia, malignancies), stenocardia, neurological disorders, stroke, epilepsy, neurodegenerative disease, myocardial infarction, liver ischemia, renal ischemia, chronic kidney disease, peripheral vascular disorders, ulcers, burns, chronic wounds, pulmonary embolism, ischemic-reperfusion injury, ischemic-reperfusion injuries associated with surgeries and organ transplantations, respiratory distress syndrome,
  • ischemic disorders including,
  • treatment does not necessarily mean total cure. Any alleviation of any undesired signs or symptoms of the disease to any extent or the slowing down of the progress of the disease can be considered treatment. Furthermore, treatment may include acts that may worsen the patient's overall feeling of well being or appearance. Treatment may also include lengthening the life of the patient, even if the symptoms are not alleviated, the disease conditions are not ameliorated, or the patient's overall feeling of well being is not improved.
  • ischemic disorders in a subject comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I, wherein the disorder is selected from the group consisting of ischemic disorders, hypoxic disorders, anemic disorders (including, but not limited to, anemia associated with autoimmune diseases, rheumatoid arthritis, systemic lupus, chronic infections such as, without limitation, HCV, and HIV, inflammatory bowel disease, chemotherapy-induced, chronic heart disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), end stage renal disease, prematurity, hypothyroidism, malnutrition, blood disorders, including but not limited to, sickle cell anemia, and ⁇ -thalassemia, malignancies), stenocardia, neurological disorders, stroke, epilepsy, neurodegenerative disease, myocardial infarction, liver ischemia, renal ischemia, chronic kidney disease, peripheral vascular disorders, ulcers,
  • a disorder in a subject comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I, wherein the disorder is selected from the group consisting of anemic disorders, neurological disorders, stroke, trauma, epilepsy, neurodegenerative disease, myocardial infarction, liver ischemia, renal ischemia, peripheral vascular disorders, ulcers, burns, bone fractures, osteoporosis, chronic wounds, pulmonary embolism, and ischemic-reperfusion injury.
  • a method of modulating the expression level of HIF and/or EPO by inhibiting the hydroxylation of HIFa, and thus stabilizing HIF and/or modulating expression of HIF-regulated genes may be useful to prevent, remedy and treat conditions associated with HIF and/or EPO including anemia, ischemia and hypoxia.
  • Ischemia, anemia, and hypoxia are three conditions associated with HIF, and include, but are not limited to, of ischemic disorders, hypoxic disorders, anemic disorders (including, but not limited to, anemia associated with autoimmune diseases, rheumatoid arthritis, systemic lupus, chronic infections such as, without limitation, HCV, and HIV, inflammatory bowel disease, chemotherapy-induced, chronic heart disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), end stage renal disease, prematurity, hypothyroidism, malnutrition, blood disorders, including but not limited to, sickle cell anemia, and ⁇ -thalassemia, malignancies), stenocardia, neurological disorders, stroke, epilepsy, neurodegenerative disease, myocardial infarction, liver ischemia, renal ischemia, chronic kidney disease, peripheral vascular disorders, ulcers, burns, chronic wounds, pulmonary embolism, ischemic-reperfusion injury, ischemic-reperfusion injuries associated with surgeries
  • the methods disclosed herein provide for stabilizing HIFa before/after the advent of the ischemia or hypoxia or in ischemia or hypoxia when the ischemia or hypoxia is associated with myocardial infarctions, strokes, or renal ischemia-reperfusion injuries.
  • ischemic- and/or hypoxic-related disorders using the compounds of Formula I-V.
  • the methods disclosed herein are advantageous for the treatment when the compounds are administered before or after the advent of ischemia or hypoxia.
  • the methods disclosed herein may reduce mortality rates and improve cardiac structure and performance after the advent of the myocardial infarction.
  • liver disorders comprising administering the compounds of Formula I before or after exposure to conditions and/or agents that are associated with liver disease.
  • hypoxia is associated with liver disease, particularly chronic liver disease that is associated with compounds toxic to the liver, such as ethanol.
  • HIFa genes known to be regulated by HIFa, for example nitric oxide synthase and glucose transporter- 1, is increased in alcoholic liver diseases.
  • ischemia or hypoxia methods for treating conditions associated with ischemia or hypoxia, where the method includes administrating to subjects a therapeutically effective amount of at least one compound of Formula I.
  • a bone disorder comprising identifying a subject in need of treatment thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • Bone disorders in the scope of the invention include bone fractures and osteoporosis.
  • the compounds of Formula I are administered to patients after the onset of conditions such as acute ischemia, for example myocardial infarction, pulmonary embolism, bowel infarction, ischemic strokes, and renal ischemia-reperfusion injuries.
  • acute ischemia for example myocardial infarction, pulmonary embolism, bowel infarction, ischemic strokes, and renal ischemia-reperfusion injuries.
  • the compounds of Formula I are administered to patients after the patients are diagnosed with conditions associated with chronic ischemia, for example, without limitation, cardiachepatopathy, macular degeneration, pulmonary embolism, acute respiratory dysfunction, neonatal respiratory distress syndrome, and congestive heart failure.
  • the compounds of Formula I are administered to patients after trauma or injuries.
  • ischemic or hypoxic conditions include, but are not limited to, atherosclerotic patients.
  • Risk factors in atherosclerosis include, for example without limitation, hyperlipidemia, smoking, hypertension, diabetes, hyperinsulinemia, and visceral obesity.
  • methods for preventing or mitigating ischemic tissue injuries where the method includes administrating to subjects in need thereof a therapeutically effective amount of a compound of Formula I.
  • the compounds disclosed herein may be administered to treat conditions, such as, hypertension, diabetes, obliterative artery disease, chronic venous insufficiency, Raynaud's disease, chronic ulcer of skin, bone fractures, osteoporosis, hepatopathy, congestive heart failure, and systemic sclerosis.
  • conditions such as, hypertension, diabetes, obliterative artery disease, chronic venous insufficiency, Raynaud's disease, chronic ulcer of skin, bone fractures, osteoporosis, hepatopathy, congestive heart failure, and systemic sclerosis.
  • the methods disclosed herein are used to stimulate angiogenesis and/or formation of granulation tissue in injured tissues, and ulcers.
  • the compounds disclosed herein are effective in stimulating the formation of granulation tissue in the wound healing processes. Secretion of growth factors from inflammatory cells, blood platelets, and activated endothelia stimulates the translocation of fibroblast and endothelial cells and the growth in the granulation tissues.
  • the methods disclosed herein are effective in stimulating the formation of granulation tissues. Accordingly, disclosed herein are methods for treating, for example, patients suffering from tissue injuries due to infarctions, patients suffering from injuries induced by trauma , or patients suffering from chronic injuries or ulcers caused by disorders, such as, diabetes.
  • the methods disclosed herein include administering to subjects in need thereof a therapeutically effective amount of a compound of Formula I.
  • ischemia-reperfusion injuries are methods for pre-treating subjects to reduce or prevent the development of tissue injuries associated with ischemia or hypoxia, by employing the compounds disclosed herein.
  • the methods disclosed herein have advantages for the treatment when the compounds are administered before the advent of the ischemia or hypoxia.
  • the methods disclosed herein reduce mortality rates and significantly improve cardiac structure and performance when the compounds disclosed herein are administered before the induction of myocardial infarction.
  • the methods disclosed herein provide a therapeutic effect associated with renal failure when the compounds disclosed herein are administered before and/or during the advent of ischemia-reperfusion injuries.
  • ischemic disorders for example, those having a history of myocardial infarction, or patients suffering from symptoms of serious ischemia, for example stenocardia.
  • the compounds disclosed herein may be administered to humans who are under conditions that are associated with possible ischemia, for example general anesthesia, or who work temporarily at high altitudes.
  • the compounds disclosed herein may be used in organ transplant procedures by previously treating organ donors with the compounds disclosed herein to maintain the organs that have been removed from the donors before the organs are transplanted into recipients.
  • a subject in need thereof comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods for regulating angiogenesis in a subject comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • vascularizing ischemic tissue in a subject comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods for vascularizing ischemic tissue in a subject comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • methods for promoting the growth of skin graft replacements comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods for promoting the growth of skin graft replacements comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • GTR guided tissue regeneration
  • methods for promoting tissue repair in the context of guided tissue regeneration (GTR) procedures comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods for promoting tissue repair in the context of guided tissue regeneration (GTR) procedures comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • disclosed herein are methods for treating anemia in a subject comprising identifying a subject in need thereof and administering to the subject, or contacting the subject with, a therapeutically effective amount of at least one compound of Formula I.
  • methods for treating anemia in a subject comprising identifying a subject in need thereof and administering to the subject, or contacting the subject with, a therapeutically effective amount of at least one compound of Formula I.
  • a subject in need thereof comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods for regulating anemia in a subject comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • a subject in another aspect, disclosed herein are methods for preventing anemia in a subject comprising identifying a subject in need thereof and administering to the subject a therapeutically effective amount of at least one compound of Formula I.
  • methods for preventing anemia in a subject comprising identifying a subject in need thereof and contacting the subject with a therapeutically effective amount of at least one compound of Formula I.
  • EPO endogenous erythropoietin
  • these methods may be used in vivo or in vitro, for example in cell culture-controlled media.
  • methods for increasing the level of endogenous EPO to prevent, remedy or treat conditions associated with deficient EPO levels or where increased EPO would be beneficial, such as in stroke patients, conditions associated with anemia and neurological disorders, e.g., Parkinson's disease.
  • the conditions associated with decreased EPO levels include anemias, disorders such as acute or chronic renal diseases, diabetes, cancers, ulcers, acute or chronic infections, e.g., viral infections, such as HIV, bacterial infections, or parasitic infections; inflammatory disorders, autoimmune diseases, malignancies, severe trauma including thermal trauma, etc. These conditions are generally those that result in anemia in a subject.
  • the methods disclosed herein are used to treat anemia associated with treatment procedures, such as radiation therapy, chemotherapy, dialysis, or surgery.
  • disorders associated with anemia include abnormal hemoglobin and/or hematocyte levels that are found in the disorders such as microcytic anemia, hypochromic anemia, aplastic anemia, etc.
  • the methods disclosed herein may be used to increase endogenous EPO levels in subjects undergoing prevention or certain treatment procedures. Examples include HIV-infected anemic subjects being treated with azidothymidine (zidovudin) or other reverse transcriptase inhibitors, patients receiving cyclic cisplatin- or non- cisplatin-containing chemotherapy, or anemic or non-anemic patients scheduled for surgical operations.
  • the methods of increasing endogenous EPO levels may be used to prevent, pre-treat or treat EPO-related conditions that are associated with nerve injuries or degeneracy of nerve tissues, including, but not limited to, stroke, trauma, epilepsy, spinal cord injury, and neurodegenerative disorders.
  • the methods disclosed herein may be used to reduce the need for allogenic blood transfusions in anemic or non-anemic patients scheduled for surgery, such as joint replacement, or to facilitate autologous blood collection prior to surgery by increasing endogenous EPO levels. These methods would reduce the risk associated with non-autologous blood transfusions such as, without limitation, transmission of infectious disease.
  • the methods disclosed herein may also be used to enhance physical performance, improve exercise abilities, and facilitate or strengthen aerobic conditioning. These methods may, for example, be used for athletes to facilitate their training, and for military personnel to improve energy and stamina.
  • the methods disclosed herein may be used to increase endogenous erythropoietin levels in the blood serum of animals treated in media and in vivo from cells cultured in vitro.
  • the kidney is a major in vivo source of erythropoietin
  • other organs including brain, liver and bone marrow may be made to produce erythropoietin when stimulated to do so.
  • the methods disclosed herein may be used to increase the expression of endogenous erythropoietin in various organs including brain, kidney and liver.
  • the methods disclosed herein can be used to increase cell volume and hemoglobin level in animals that are treated in vivo with the compounds disclosed herein.
  • the increase in plasma EPO, cell volume and hemoglobin levels in blood through the action of the compounds disclosed herein is sensitive to the amount of the compounds administered. It is therefore possible to establish a therapeutic regimen to produce a uniform and controlled level of the effect of the compounds disclosed herein.
  • Example 1 Synthesis of [(5-Chloro-8-hydroxy-thieno[2,3-b;4,5- c']dipyridine-7-carbonyl)-amino] -acetic acid based on Scheme 1.
  • Example 2 Synthesis of (S)-2-[(l-Hydroxy-4-methyl-9-thia-3,5-diaza- fluorene-2-carbonyl)-amino]-propionic acid based on Scheme 2.
  • Ethyl 5-chloro-3-ethylthieno[2,3-c]pyridine-2-carboxylate (780 mg, 2.89 mmol) was dissolved in CC1 4 (100 mL) and then NBS (669 mg, 3.76 mmol) and AIBN (47 mg, 0.289 mmol) were added. The resulting mixture was refiuxed for about 1 hour. Then the reaction mixture was diluted with H 2 0 (50 mL) and stirred at 80°C for 15 min. The hot organic layer was separated out, dried and concentrated to get the crude product as a white solid (720 mg, 71%), which was used for the next step straightly.
  • Biological activity of the compounds according to the present invention may be evaluated using any of the conventional known methods.
  • the suitable assays have been widely known in the art. The following assays are described for the purpose of illustration, but are in no way intended to limit the scope of the present invention.
  • the compounds of the present invention show activities in at least one of the following assays.
  • VEGF and EPO assays were washed twice with cold phosphate buffer saline (PBS), and then dissolved in a solution of 1 ml of 10 mM tris (pH 7.4), 1 mM EDTA, 150 mM NaCI, 0.5% IGEPAL (Sigma- Aldrich, St. Louis MO) and protease inhibitor mix (Roche Molecular Biochemicals) for 15 minutes while being kept in ice. Cell lysates were centrifuged at 4 °C for 5 minutes at a rotary speed of 3,000 xg, and cytosol fractions (supernatant) were collected.
  • PBS cold phosphate buffer saline
  • Nuclei (pellets) were re-suspended and dissolved in a solution of 100 ⁇ of 20 mM HEPES (pH 7.2), 400 mM NaCI, 1 mM EDTA, 1 mM dithiothreitol and protease mix (Roche Molecular Biochemicals), centrifuged at 4 °C for 5 minutes at a rotary speed of 13,000 xg, and then nuclear protein fractions (supernatant) were collected.
  • Nucleus fractions were analyzed for HIF- ⁇ using a QUANTIKINE immunoassay (R&D Systems, Inc., Minneapolis MN) according to the manufacturer's instructions.
  • HIF-PH2 HIF-PH2 (PHD2 ⁇ Assay and HIF-PH3 (PHD3 ⁇ Assay Materials
  • HIF-PH2 (EGLN1) was expressed from E.coli cells, and purified using two processes: a Ni-affinity chromatography column and a size-exclusion chromatography column.
  • HIF-PH3 (EGLN3) was expressed from E.coli cells, and purified using two process: an Ni-affinity chromatography column and a size-exclusion chromatography column
  • HIF PH2 enzyme that was first overexpressed by genetic recombination and then purified was used to perform an enzyme reaction.
  • 200nM HIF PH2 enzyme reacted with 50 nM peptide substrate (FITC-ACA-DLDLEALAPYIPADDDFQLR; SEQ ID NO.: l) in a reaction buffer (20 mM Tris-Cl (pH8.0), 100 mM NaCI, 0.5 % Nonidet P40).
  • 2 mM ascorbic acid and 5 mM ketoglutarate with 100 ⁇ FeCl 2 or without FeCl 2 were used together with crude enzyme.
  • a concentration of HIF PH2 inhibitor to be tested was treated and reacted at 30 °C for one hour. After the reaction, the resulting reaction product was boiled at 95 °C for one minute to suppress the enzyme reaction.
  • Nonidet P40 Nonidet P40
  • GST-VBC binding reaction was carried out at room temperature for 30 minutes.
  • fluorescence polarization was determined at a wavelength of 485nm/535 nm(ex/em) by using a Fusion-FP (Packard) system.
  • a fluorescence polarization value of a sample that is not treated with the HIF PH2 inhibitor was used as 100 % control, and the activities of the HIF PH2 inhibitor were measured as percentage of the remaining HIF PH2 enzyme activity in samples treated with a concentration of the HIF PH2 inhibitor to be tested.
  • HIF PH3 enzyme was overexpressed by genetic recombination in E. coli and then purified. Purified enzyme was used to perform the following enzyme reaction.
  • 200nM of HIF PH3 enzyme was reacted with 50 nM peptide substrate (FITC-ACA- DLD LEAL AP YIP ADDDFQLR) in a reaction buffer (20 mM Tris-Cl (pH 8.0), 100 mM NaCl, and 0.5 % Nonidet P40).
  • 2 mM ascorbic acid, 100 ⁇ FeCl 2 and 5 mM ketoglutarate were used together with crude enzyme.
  • a concentration of HIF PH inhibitor to be tested was treated and reacted at 30 °C for one hour. After the reaction, the resulting reaction product was boiled at 95 °C for one minute to suppress the enzyme reaction.
  • 500 nM GST-VBC (GST-VHL-Elongin B - Elongin C) protein was added to a reaction buffer (50 mM Tris-Cl (pH8.0), 120 mM NaCl, and 0.5 % Nonidet P40), and a GST-VBC binding reaction was carried out at room temperature for 30 minutes. After the reaction was completed, the fluorescence polarization was determined at a wavelength of 485nm/535nm(ex/em) by using a Fusion-FP (Packard) system.
  • a fluorescence polarization value of a sample that is not treated with the HIF PH inhibitor was used as 100 % control, and the activities of the HIF PH inhibitor were measured as percentage of the remaining HIF PH3 enzyme activity in samples treated with a concentration of the HIF PH inhibitor to be tested.
  • the remaining HIF PH3 enzyme activities after the treatment with increasing concentrations of the HIF PH inhibitor was measured to calculate IC 50 of the HIF PH inhibitor, and then a concentration of the inhibitor was determined as IC 50 , the concentration at which 50 % of HIF PH3 enzyme activity is inhibited compared to the control.
  • Hep3B hepatocarcinoma
  • DMEM fetal calf serum
  • a luciferase assay was used to determine the changes in transcription amount of EPO and VEGF genes in cells.
  • a human HIFla gene was first cloned into an animal cell expression vector, pFlag-CMV, to prepare a pFlag-HIFla vector, and a hypoxia responsible element (HRE) sequence of an EPO gene 3 '-enhancer domain was then cloned upstream of luciferase and TK promoter genes to prepare a pEPO HRE-Luc expression vector.
  • HRE hypoxia responsible element
  • the promoter and luciferase domains of the VEGF gene were cloned into a pGL3 -basic vector to prepare a pVEGF-Luc expression vector.
  • HeLa cells were seed-cultured in a medium dish to grow to about 70-80% density one day before the HeLa cells were to be used.
  • the HeLa cells were transfected with each of the prepared pEPO HRE-Luc and pVEGF-Luc expression vectors together with the pFlag-HIFla and the Renilla luciferase expression vector (Promega, Madison, WI, USA), by using LipofectAMINE PLUSTM (Invitrogen Life Technologies, Carlsbad CA).
  • the medium was exchanged with DMEM, 1% Penicillin- Streptomycin in 10% FBS supplemented with serum.
  • cultured cells were treated with each of the compounds at the concentrations indicated.
  • the cells were cultured for 24 hrs in an incubator that was maintained under conditions of 37 °C, 20%) 0 2 and 5%> C0 2 .
  • PBS cold phosphate buffer saline
  • Luciferase activity of the cells was measured using the dual luciferase assay system (Promega, Madison, WI, USA).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de pyridine, ou un ester, un amide un promédicament ou un sel pharmaceutiquement acceptable de ceux-ci, des compositions pharmaceutiques en contenant et des procédés de modulation du niveau ou de l'activité des HIF chez un sujet, d'inhibition de l'hydroxylation de l'HIFα chez un sujet, de modulation de l'expression de gènes régulés par les HIF chez un sujet, de traitement d'une affection associée aux HIF chez un sujet, de renforcement des niveaux en EPO endogène chez un sujet ou de traitement d'une affection chez un sujet, au moyen des composés décrits.
PCT/US2010/054687 2009-11-05 2010-10-29 Dérivés de pyridine et leurs procédés d'utilisation WO2011056725A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25838209P 2009-11-05 2009-11-05
US61/258,382 2009-11-05

Publications (1)

Publication Number Publication Date
WO2011056725A1 true WO2011056725A1 (fr) 2011-05-12

Family

ID=43970279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054687 WO2011056725A1 (fr) 2009-11-05 2010-10-29 Dérivés de pyridine et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2011056725A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2019028150A1 (fr) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions destinées à être utilisées dans des méthodes de traitement des hémoglobinopathies
CN114315845A (zh) * 2020-09-28 2022-04-12 江苏绿人半导体有限公司 一种有机化合物及在有机电致发光器件中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270699A1 (en) * 2001-12-06 2006-11-30 Fibrogen, Inc. Stabilization of hypoxia inducible factor (HIF) alpha
US20080213404A1 (en) * 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
US20080293763A1 (en) * 2003-06-06 2008-11-27 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270699A1 (en) * 2001-12-06 2006-11-30 Fibrogen, Inc. Stabilization of hypoxia inducible factor (HIF) alpha
US20080293763A1 (en) * 2003-06-06 2008-11-27 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
US20080213404A1 (en) * 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARKAR ET AL.: "Adenoviral transfer of HIF-1a enhances vascular responses to critical limb ischemia in diabetic mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 4, 3 November 2009 (2009-11-03), pages 18769 - 18774, XP055239317, DOI: doi:10.1073/pnas.0910561106 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2019028150A1 (fr) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions destinées à être utilisées dans des méthodes de traitement des hémoglobinopathies
CN114315845A (zh) * 2020-09-28 2022-04-12 江苏绿人半导体有限公司 一种有机化合物及在有机电致发光器件中的应用

Similar Documents

Publication Publication Date Title
US20110028507A1 (en) Pyridine derivatives and methods of use thereof
US10647711B2 (en) Azepin-2-one derivatives as RSV inhibitors
WO2010018458A2 (fr) Dérivés de phénol et leurs procédés d'utilisation
EP2443104B1 (fr) Antagonistes de la voie de la protéine hedgehog de phtalazine disubstituée
ES2660914T3 (es) Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
MX2010013773A (es) Compuestos de 2,4'-bipiridinilo como inhibidores de cinasa d de proteina utiles para el tratamiento de, entre otras, insuficiencia cardiaca ia y cancer.
TW200938191A (en) Hepatitis C virus inhibitors
KR20180021820A (ko) Ido 억제제
EP3842423A1 (fr) Dérivé de 3-azabicyclo[3,1,1]heptane et composition pharmaceutique le comprenant
CN111801100A (zh) 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物
EP3388428A1 (fr) Inhibiteur de la voie wnt amides hétérocycliques à cinq chaînons
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
EP2895166A1 (fr) Dérivés d'aminoisoquinoline utilisables en tant qu'inhibiteurs des protéines kinases
KR20130118731A (ko) 항증식성 질환 치료에 사용하기 위한 ｐｉ3ｋ 억제제로서 피페라지노트리아진
WO2011056725A1 (fr) Dérivés de pyridine et leurs procédés d'utilisation
JP2021512867A (ja) Ｉｒａｋ阻害剤としてのキノリン化合物及びその使用
US11993613B2 (en) Thiazolo[5,4-b]pyridine MALT-1 inhibitors
WO2021063362A1 (fr) Composé de biaryle substitué par sulfo ou sel correspondant, son procédé de préparation et son utilisation
WO2018028491A1 (fr) Inhibiteurs indoamine2, 3-dioxygénase et leurs utilisations en pharmacie
JP2022501397A (ja) Ｐｄ−ｌ１拮抗薬化合物
AU2016304331B2 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
CN101553476A (zh) 作为有丝分裂驱动蛋白抑制剂的二唑和噻二唑衍生物及其使用方法
CA3197092A1 (fr) Derives de 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide utilises en tant qu'inhibiteurs de vhl pour le traitement de l'anemie et du cance
CN113754635A (zh) 稠环类化合物及其制备方法和用途
CN110724076B (zh) 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10828940

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13.11.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10828940

Country of ref document: EP

Kind code of ref document: A1